Galectin Therapeutics Statistics
Share Statistics
Galectin Therapeutics has 62.31M shares outstanding. The number of shares has increased by 4.52% in one year.
| Shares Outstanding | 62.31M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.21% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 43.43M |
| Failed to Deliver (FTD) Shares | 7.12K |
| FTD / Avg. Volume | 2.95% |
Short Selling Information
The latest short interest is 5.52M, so 8.79% of the outstanding shares have been sold short.
| Short Interest | 5.52M |
| Short % of Shares Out | 8.79% |
| Short % of Float | 12.66% |
| Short Ratio (days to cover) | 42.37 |
Valuation Ratios
The PE ratio is -2.43 and the forward PE ratio is -1.76.
| PE Ratio | -2.43 |
| Forward PE | -1.76 |
| PS Ratio | 0 |
| Forward PS | 3.6 |
| PB Ratio | -1.66 |
| P/FCF Ratio | -3.03 |
| PEG Ratio | n/a |
Enterprise Valuation
Galectin Therapeutics Inc. has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 1.77, with a Debt / Equity ratio of -1.19.
| Current Ratio | 1.77 |
| Quick Ratio | 1.77 |
| Debt / Equity | -1.19 |
| Total Debt / Capitalization | 623.83 |
| Cash Flow / Debt | -0.46 |
| Interest Coverage | -14.86 |
Financial Efficiency
Return on equity (ROE) is 0.68% and return on capital (ROIC) is -329.17%.
| Return on Equity (ROE) | 0.68% |
| Return on Assets (ROA) | -1.46% |
| Return on Capital (ROIC) | -329.17% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -2.93M |
| Employee Count | 14 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 31.25% in the last 52 weeks. The beta is 0.63, so Galectin Therapeutics 's price volatility has been higher than the market average.
| Beta | 0.63 |
| 52-Week Price Change | 31.25% |
| 50-Day Moving Average | 2.59 |
| 200-Day Moving Average | 2.65 |
| Relative Strength Index (RSI) | 36.43 |
| Average Volume (20 Days) | 241.81K |
Income Statement
In the last 12 months, Galectin Therapeutics had revenue of $0 and earned -$41.07M in profits. Earnings per share was $-0.74.
| Revenue | 0 |
| Gross Profit | -33.00K |
| Operating Income | -38.07M |
| Net Income | -41.07M |
| EBITDA | -202.00K |
| EBIT | - |
| Earnings Per Share (EPS) | -0.74 |
Balance Sheet
The company has $25.66M in cash and $71.81M in debt, giving a net cash position of -$46.15M.
| Cash & Cash Equivalents | 25.66M |
| Total Debt | 71.81M |
| Net Cash | -46.15M |
| Retained Earnings | -354.37M |
| Total Assets | 28.97M |
| Working Capital | 3.41M |
Cash Flow
In the last 12 months, operating cash flow was -$32.97M and capital expenditures $0, giving a free cash flow of -$32.97M.
| Operating Cash Flow | -32.97M |
| Capital Expenditures | 0 |
| Free Cash Flow | -32.97M |
| FCF Per Share | -0.55 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
GALT does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -35.24% |
| FCF Yield | -25.13% |
Analyst Forecast
The average price target for GALT is $11, which is 423.8% higher than the current price. The consensus rating is "Buy".
| Price Target | $11 |
| Price Target Difference | 423.8% |
| Analyst Consensus | Buy |
| Analyst Count | 1 |
Stock Splits
The last stock split was on Mar 23, 2012. It was a backward split with a ratio of 1:6.
| Last Split Date | Mar 23, 2012 |
| Split Type | backward |
| Split Ratio | 1:6 |
Scores
| Altman Z-Score | -22.67 |
| Piotroski F-Score | 2 |